Ustekinumab
- Generic Name
- Ustekinumab
- Brand Names
- Stelara, Pyzchiva, Uzpruvo, Wezenla, Steqeyma, Otulfi, Fymskina, Eksunbi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 815610-63-0
- Unique Ingredient Identifier
- FU77B4U5Z0
- Background
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMAR...
- Indication
Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in patients 6 years of age and older who are candidates for phototherapy or systemic therapy. In adult patients, it is also indicated for the management of active psoriatic arthritis (PsA) alone or in combination with methotrexate, moderately to severely active Crohn’s disease...
- Associated Conditions
- Severe Plaque psoriasis, Ulcerative Colitis, Active Severe, Active Psoriatic arthritis, Moderate Plaque psoriasis, Moderate Ulcerative colitis, Moderate, active Crohn´s Disease, Severe, active Crohn´s Disease
- Associated Therapies
- -
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 20
- Registration Number
- NCT04089345
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU de Liège, Sart Tilman, Liège, Belgium
🇧🇪UZ Leuven, Leuven, Vlaanderen, Belgium
Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 685
- Registration Number
- NCT03942120
- Locations
- 🇰🇷
Changwon Kyunngsang University Hospital, Changwonsi, Korea, Republic of
🇰🇷Good Gangan Hospital, Busan, Korea, Republic of
🇰🇷Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 66
- Registration Number
- NCT03941132
- Locations
- 🇨🇦
BCDiabetes, Vancouver, British Columbia, Canada
🇨🇦Mount Sinai Hospital/UHN, Toronto, British Columbia, Canada
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1158
- Registration Number
- NCT03926130
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Digestive Health Specialists, Tupelo, Mississippi, United States
🇺🇸GastroIntestinal Biosciences Clinical Trials, Los Angeles, California, United States
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 203
- Registration Number
- NCT03881059
- Locations
- 🇺🇸
San Marcus Research Clinic, Miami Lakes, Florida, United States
🇺🇸Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸Arthritis Associates, Hattiesburg, Mississippi, United States
Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Hospices Civils de Lyon
- Registration Number
- NCT03712826
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 20
- Registration Number
- NCT03629379
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Cilag S.A.S.
- Target Recruit Count
- 111
- Registration Number
- NCT03606499
- Locations
- 🇫🇷
CHU de Nancy - Hôpital de Brabois, Vandoeuvre les Nancy, France
Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT03495973
- Locations
- 🇸🇪
Universitetssjukhuset Örebro, Örebro, Sweden
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1409
- Registration Number
- NCT03466411
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Morehouse School of Medicine, Atlanta, Georgia, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.